← Back to Screener
Barinthus Biotherapeutics plc American Depositary Shares (BRNS)
Price$0.59
Favorite Metrics
Price vs S&P 500 (26W)-65.36%
Price vs S&P 500 (4W)-15.84%
Market Capitalization$24.14M
All Metrics
Book Value / Share (Quarterly)$1.82
P/TBV (Annual)0.46x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)282.25%
Cash Flow / Share (Quarterly)$-1.18
Price vs S&P 500 (YTD)-19.86%
Net Profit Margin (TTM)-54.21%
EPS (TTM)$-1.12
10-Day Avg Trading Volume0.02M
EPS Excl Extra (TTM)$-1.12
Revenue Growth (5Y)16.92%
EPS (Annual)$-1.64
ROI (Annual)-89.52%
Net Profit Margin (5Y Avg)-5777.69%
Cash / Share (Quarterly)$1.72
ROA (Last FY)-67.67%
EBITD / Share (TTM)$-1.06
ROE (5Y Avg)-38.75%
Operating Margin (TTM)-62.66%
Cash Flow / Share (Annual)$-1.18
P/B Ratio0.33x
P/B Ratio (Quarterly)0.37x
Net Income / Employee (Annual)$-5
Net Interest Coverage (TTM)-15.07x
ROA (TTM)-38.90%
EPS Incl Extra (Annual)$-1.64
Current Ratio (Annual)7.76x
Quick Ratio (Quarterly)7.30x
3-Month Avg Trading Volume0.05M
52-Week Price Return-16.31%
EV / Free Cash Flow (Annual)-22.91x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.47
P/S Ratio (Annual)1.61x
Asset Turnover (Annual)0.09x
52-Week High$2.92
Operating Margin (5Y Avg)-6672.17%
EPS Excl Extra (Annual)$-1.64
CapEx CAGR (5Y)-33.75%
26-Week Price Return-56.62%
Quick Ratio (Annual)7.30x
13-Week Price Return-21.83%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)7.76x
Enterprise Value$-46.314
Revenue / Share Growth (5Y)13.60%
Asset Turnover (TTM)0.08x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-409.03%
Cash / Share (Annual)$1.72
3-Month Return Std Dev72.59%
Net Income / Employee (TTM)$-3
ROE (Last FY)-89.52%
EPS Basic Excl Extra (Annual)$-1.64
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.12
Receivables Turnover (Annual)0.27x
ROI (TTM)-49.57%
P/S Ratio (TTM)1.61x
Pretax Margin (5Y Avg)-5880.15%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$1.47
Price vs S&P 500 (52W)-51.41%
Year-to-Date Return-15.73%
5-Day Price Return7.27%
EPS Normalized (Annual)$-1.64
ROA (5Y Avg)-31.22%
Net Profit Margin (Annual)-408.00%
Month-to-Date Return3.69%
Cash Flow / Share (TTM)$-1.89
EBITD / Share (Annual)$-1.55
Operating Margin (Annual)-454.07%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-38.74%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.12
P/TBV (Quarterly)0.46x
P/B Ratio (Annual)0.37x
Pretax Margin (TTM)-54.33%
Book Value / Share (Annual)$1.82
Price vs S&P 500 (13W)-24.70%
Beta-0.54x
Revenue / Share (TTM)$0.00
ROE (TTM)-49.57%
52-Week Low$0.51
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
BRNSBarinthus Biotherapeutics plc American Depositary Shares | 1.61x | — | — | — | $0.59 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapies designed to treat chronic infectious diseases, autoimmune disorders, and cancer. The company operates a single business segment focused on the research and development of immunotherapies and vaccine candidates.